Evidence map›Paper›PMID 8794337›Full record

ArticleJournal of virology1996

Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site.

S L Schafer, J Vlach, P M Pitha

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Molecular pathways in virus-induced cytokine production.Microbiology and molecular biology reviews : MMBR · 2001
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

S L SchaferOncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.
J Vlach
P M Pitha
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

THE ROLE OF CYTOKINES IN THE PATHOGENESIS OF AIDSR37AI026123 · NIAID · JOHNS HOPKINS UNIVERSITY · PI PITHA-ROWE, PAULA M · 1991 to 2000
$324k
ROLE OF INTERFERON ON THE PATHOGENESIS OF AIDSR01AI026123 · NIAID · JOHNS HOPKINS UNIVERSITY · PI PITHA-ROWE, PAULA M · 1988 to 1990
–
ENHANCEMENT OF INFECTION IN MO WITH LENTIVIRUSES SIV HIVR01AI029382 · NIAID · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NARAYAN, OPENDRA · 1989 to 1993
–
NIAID NIH HHS AI26123NIAID NIH HHS AI29382
6 · The paper itself

Abstract

Expression of human immunodeficiency virus type 1 (HIV-1) provirus can be stimulated by herpes simplex virus type 1 (HSV-1) infection; the stimulation occurs at the level of transcriptional activation of the HIV long terminal repeat (LTR) and is mediated by both cellular and HSV-1-encoded transactivators. We have shown in this study that HSV-1 immediate-early gene ICP0 cooperates effectively with the HIV-1-encoded transactivator, Tat, in the stimulation of HIV-1 LTR-directed transcription. The cooperation between ICP0 and Tat is specific for the HIV-1 LTR and was not observed with other promoters (e.g., ICP0) that can be transactivated by ICP0 but not by Tat. Analyses of HIV-1 LTR deletion mutants have shown that ICP0 not only transactivates an HIV-1 LTR mutant that is unresponsive to NF-kappaB and Tat-mediated transactivation, such as the HIV-1 LTR with the enhancer deleted (-83 LTR) and TAR deleted (+20 to +81), but also restores responsiveness to Tat. ICP0 also showed cooperation with Gal4-Tat fusion protein-mediated transactivation of Gal4-HIV-1 LTR with TAR deleted. Enhancement of the transcriptional activation of ICP0 by Tat requires both the cysteine-rich and core domains of Tat and is inhibited by RO5-3335. ICP0 stimulates transcription of not only the HIV-1 LTR but also the TAR-defective HIV-1 provirus. We suggest that ICP0 can (i) recruit Tat to the vicinity of the HIV-1 promoter, thereby providing an alternative binding site for Tat, and (ii) substitute for the enhancer-binding proteins that are required for efficient Tat transactivation in T cells.

Indexed as

Genes, tatBinding SitesGene Products, tatHerpesvirus 1, HumanHIV-1HIV Long Terminal RepeatHumansImmediate-Early Proteinstat Gene Products, Human Immunodeficiency VirusTranscriptional ActivationUbiquitin-Protein LigasesGene Products, tatImmediate-Early Proteinstat Gene Products, Human Immunodeficiency VirusUbiquitin-Protein LigasesVmw110 protein, Human herpesvirus 1

Identifiers

PMID8794337
PMCPMC190743
OpenAlexW1519441167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.